SCHEMBL23930528

SCHEMBL23930528

O=C(CBr)c1cc(-c2ccncc2)no1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.43
RAB9A P51151 1/20 0.43
USP30 Q70CQ3 2/20 0.43
ROCK2 O75116 1/20 0.39
PRKCA P17252 1/20 0.39
GRK2 P25098 1/20 0.39
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 1/20 0.38
S1PR1 P21453 1/20 0.38
PTPN1 P18031 3/20 0.38
GPR142 Q7Z601 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
KDM4E B2RXH2 1/20 0.36
NAMPT P43490 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1435521 0.86 RAB9A (0.59) SMN1; SMN2RAB9AUSP30MEN1ALDH1A1
SCHEMBL23930576 0.84 CYP2C9 (0.54) SMN1; SMN2RAB9AUSP30KMT2ACYP1A2
SCHEMBL5802479 0.83 MEN1 (0.52) SMN1; SMN2RAB9AMEN1ALDH1A1KMT2A
SCHEMBL2097094 0.83 NOTUM (0.53) SMN1; SMN2RAB9AUSP30MEN1ALDH1A1
SCHEMBL3533246 0.80 SMN1; SMN2 (0.51) SMN1; SMN2RAB9AUSP30ROCK2PRKCA
SCHEMBL9372186 0.80 SMN1; SMN2 (0.43) SMN1; SMN2RAB9AMEN1KMT2APTPN1
SCHEMBL24708022 0.79 MAPT (0.40) SMN1; SMN2RAB9AMEN1ALDH1A1KMT2A
SCHEMBL23930594 0.79 RAB9A (0.50) SMN1; SMN2RAB9AUSP30ROCK2PRKCA
SCHEMBL3822977 0.79 GSK3B (0.51) SMN1; SMN2RAB9AALDH1A1KMT2A
SCHEMBL3820935 0.78 MME (0.47) SMN1; SMN2RAB9AMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115697979-B Substituted aminothiazoles as DGKZETA inhibitors for immune activation 拜耳公司 2025-06-24 CN disclosed
EP-4139287-B1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AG (DE) 2025-02-26 EP disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
EP-4139287-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2023-03-01 EP disclosed
CN-115697979-A Substituted aminothiazoles as DGKZETA inhibitors for immune activation 拜耳公司 2023-02-03 CN disclosed
WO-2021214020-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG SMN1; SMN2 4815/4885RAB9A 949/4885USP30 3248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.